Here are five observations:
1. For the second quarter, the company’s sales topped $111.5 million, a 2.4 percent increase year-over-year.
2. Orthofix’s spine fixation business segment generated $23.9 million in sales, an 11.8 percent increase year-over-year.
3. Within its biologics segment, Orthofix reported $17.7 million in sales, a 6.3 percent decrease year-over-year.
4. Orthofix reported $24.8 million in sales for its extremity fixation segment, a 0.2 percent increase year-over-year.
5. The company predicts its full-year sales to range between $450 million to $456 million.
To view the full financial report, click here.
More articles on devices and implants:
Fuse Medical completes Maxim Surgical acquisition
Alphatec sets sights on 12 new product launches: 3 things to know about the rest of the year
Zimmer Biomet names 2 industry veterans to board of directors — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
